Wells Fargo lowered the firm’s price target on Elevance Health to $597 from $609 and keeps an Overweight rating on the shares. The firm’s bottom-up analysis of over 2,000 stat filings suggests the potential for meaningful Medicaid margin pressure.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ELV:
- Elevance Health price target lowered to $571 from $581 at Deutsche Bank
- 10 Stocks to Buy Before Their Ex-Dividend Dates Arrive, Week of March 6, 2023
- Elevance Health price target raised to $572 from $555 at JPMorgan
- Managed care stocks pressured after CMS’ preliminary Medicare Advantage rates
- Elevance Health price target raised to $565 from $550 at Loop Capital
